OnCusp
Manufacturing · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
433 Broadway, New York City, New York, 1...Phone Number
(646) 585-2168Website
www.oncusptx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About OnCusp
OnCusp Therapeutics is a global biopharmaceutical company translating a focused portfolio of first-in-class oncology assets from promising research into proven medicines. The company is led by a founding team that has deep experience in business development, clinical development and building start-up biopharmaceutical company.Explore more
OnCusp Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is OnCusp your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on OnCusp recently announced quarterly report
OnCusp, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if OnCusp is spiking on competitors!
Website visits: Recent activity has been detected on your website
Click to see if OnCusp had a recent Job posting/layoffs
Check if OnCusp has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at OnCusp
Funding: Get notified immidiatlly once OnCusp has new funding data
Product Launch: Get notified when OnCusp launches new products
Recommended Actions
Find VP level buyers at OnCusp
Find more new buyers
Compare Similar Companies to OnCusp
Compare insights from companies similar to OnCusp, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
OnCusp
<$5M
1-10
Private
$125M
2020
Bing YuanCo-Founder & CEO & Chief Everything Officer & Humble Entrepreneur
Company Profile Activity
Activity Insights
OnCusp is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
OnCusp is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about OnCusp.
OnCusp financials insights
Gather financial insights about OnCusp, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Angel/Seed
$25M
2024
Series A
$100M
OnCusp Tech Stack
A closer look at the technologies used by OnCusp
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Event
Events, Engineering, Research & Development, Training, Machine Learning, Learning & Development, Search, Laboratory Operations, Medical Education & Training, Medical Research, Chemical Engineering, Artificial Intelligence, Clinical Operations, Healthcare Technology, HR Operations, Operations
Funding
OnCusp News & Media
OnCusp Therapeutics appoints CMO | The Pharmaletter
New Jersey, USA-based clinical-stage biotech OnCusp Therapeutics has announced the appointment of Dr Dimitry Nuyten as chief medical officer (CMO).OnCusp Therapeutics Appoints Dimitry Nuyten, M.D., Ph.D., as Chief Medical Officer
PRINCETON, N.J., June 23, 2025 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, today announced the appointment of Dimitry S.A....OnCusp Therapeutics Announces Encouraging Initial Phase 1a Results from Ongoing First-in-Human Study Evaluating its CDH6-Directed Antibody-Drug Conjugate, CUSP06, in Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors at the 2025 ASCO Annual Meeting
CUSP06 is a CDH6-directed ADC with a differentiated profile and potentially best-in-class activity CUSP06 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor ADCs Promising signs of efficacy were observed in patients with heavily pretreated platinum-resistant...OnCusp Therapeutics Receives FDA Fast Track Designation for CUSP06 for the Treatment of Platinum-Resistant Ovarian Cancer
PRINCETON, N.J., Feb. 12, 2025 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to CUSP06, a Cadherin-6 targeting Antibody-Drug Conjugate (CDH6 ADC) and the company's lead program, for the treatment of patients with platinum-resistant ov
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding OnCusp
Sign Up For FreeTo access detailed company insights
OnCusp Therapeutics is a global biopharmaceutical company translating a focused portfolio of first-in-class oncology assets from promising research into proven medicines. The company is led by a founding team that has deep experience in business development, clinical development and building start-up biopharmaceutical company.... Read More
